VIREAD

Peak

tenofovir disoproxil fumarate

NDAORALPOWDERPriority Review
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21

Mechanism of Action

12.1 Mechanism of Action Tenofovir disoproxil fumarate is an antiviral drug [see ]. 12.3 Pharmacokinetics The pharmacokinetics of TDF have been evaluated in healthy volunteers and HIV-1 infected individuals. Tenofovir pharmacokinetics are similar between these populations. Absorption VIREAD is a…

Clinical Trials (5)

NCT06816043Phase 1Completed

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

Started Feb 2025
20 enrolled
Healthy
NCT06101342Phase 2Active Not Recruiting

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Started Dec 2023
181 enrolled
Pre-Exposure Prophylaxis of HIV Infection
NCT06101329Phase 2Active Not Recruiting

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Started Nov 2023
253 enrolled
Pre-Exposure Prophylaxis of HIV Infection
NCT03251144Phase 1/2Completed

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

Started Apr 2019
26 enrolled
HIV/AIDSAntiviral ToxicityAntiviral Drug Adverse Reaction+1 more
NCT03547908Phase 3Completed

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Started May 2018
244 enrolled
HIV-1/HBV Co-Infection